Is Europe ready to embrace a policy of universal varicella vaccination?*
- 11 September 2005
- journal article
- review article
- Published by Hindawi Limited in International Journal Of Clinical Practice
- Vol. 59 (11) , 1326-1333
- https://doi.org/10.1111/j.1742-1241.2005.00647.x
Abstract
For the first time, a live attenuated varicella vaccine with an indication for universal vaccination is licensed in all EU countries. It is now time to consider whether in Europe there should be widespread vaccination against varicella to prevent this common and highly infectious disease. Increasing numbers of countries are adopting vaccination programmes against the disease. In those countries where a routine vaccination policy has been adopted, the success of the vaccine has been significant. The USA, which prior to the launch of a universal vaccination programme in 1995 had 4 million cases of varicella per year, has seen a dramatic reduction in varicella morbidity and mortality rates. A universal varicella vaccination policy is an option that needs to be considered for Europe not only in medical terms but also because it would be socially and economically appropriate.Keywords
This publication has 33 references indexed in Scilit:
- Ten year follow-up of healthy children who received one or two injections of varicella vaccineThe Pediatric Infectious Disease Journal, 2004
- Epidemiology of varicella-zoster virus in England and WalesJournal of Medical Virology, 2003
- Hospitalizations for varicella in the United States, 1988 to 1999The Pediatric Infectious Disease Journal, 2002
- Contacts with varicella or with children and protection against herpes zoster in adults: a case-control studyThe Lancet, 2002
- A comparison of safety, tolerability and immunogenicity of Oka/Merck varicella vaccine and VARILRIX? in healthy children*1Vaccine, 2002
- The Effect of Vaccination on the Epidemiology of Varicella Zoster VirusJournal of Infection, 2002
- Varicella Outbreaks After Vaccine Licensure: Should They Make You Chicken?Published by American Academy of Pediatrics (AAP) ,1999
- Safety and immunogenicity of concurrent administration of measles-mumps-rubellavaricella vaccine and PedvaxHIB® vaccines in healthy children twelve to eighteen months oldThe Pediatric Infectious Disease Journal, 1997
- Oka/Merck varicella vaccine in healthy children: final report of a 2-year efficacy study and 7-year follow-up studiesVaccine, 1991
- Centers for Disease ControlThe Pediatric Infectious Disease Journal, 1984